Novartis’s NASH Chief: Our Strategy Is Combos With Tropifexor As ‘Backbone’

Novartis's broad but early-stage NASH pipeline will use FXR agonist tropifexor as its keystone for developing combination therapies with outside partners.

Liver
Novartis's NASH Chief Says Program is gradually growing • Source: Shutterstock

Novartis AG's NASH strategy can be summed up in one word: "combinations."

That's how the Swiss pharma's NASH program head, in an interview with Scrip, described his approach to developing therapies to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category